Recommendations from the iSBTc-SITC/FDA/NCI workshop on immunotherapy biomarkers

Lisa H. Butterfield, A. Karolina Palucka, Cedrik M. Britten, Madhav V. Dhodapkar, Leif Håkansson, Sylvia Janetzki, Yutaka Kawakami, Thomas Oliver Kleen, Peter P. Lee, Cristina Maccalli, Holden T. Maecker, Vernon C. Maino, Michele Maio, Anatoli Malyguine, Giuseppe Masucci, Graham Pawelec, Douglas M. Potter, Licia Rivoltini, Lupe G. Salazar, Dolores J. SchendelCraig L. Slingluff, Wenru Song, David F. Stroncek, Hideaki Tahara, Magdalena Thurin, Giorgio Trinchieri, Sjoerd H. Van Der Burg, Theresa L. Whiteside, Jon M. Wigginton, Francesco Marincola, Samir Khleif, Bernard A. Fox, Mary L. Disis

研究成果: Review article査読

89 被引用数 (Scopus)

抄録

Purpose: To facilitate development of innovative immunotherapy approaches, especially for treatment concepts exploiting the potential benefits of personalized therapy, there is a need to develop and validate tools to identify patients who can benefit from immunotherapy. Despite substantial effort, we do not yet know which parameters of antitumor immunity to measure and which assays are optimal for those measurements. Experimental Design: The iSBTc-SITC (International Society for Biological Therapy of Cancer-Society for Immunotherapy of Cancer), FDA (Food and Drug Administration), and NCI (National Cancer Institute) partnered to address these issues for immunotherapy of cancer. Here, we review the major challenges, give examples of approaches and solutions, and present our recommendations. Results and Conclusions: Although specific immune parameters and assays are not yet validated, we recommend following standardized (accurate, precise, and reproducible) protocols and use of functional assays for the primary immunologic readouts of a trial; consideration of central laboratories for immune monitoring of large, multi-institutional trials; and standardized testing of several phenotypic and functional potential potency assays specific to any cellular product. When reporting results, the full QA (quality assessment)/QC (quality control) should be conducted and selected examples of truly representative raw data and assay performance characteristics should be included. Finally, to promote broader analysis of multiple aspects of immunity, and gather data on variability, we recommend that in addition to cells and serum, RNA and DNA samples be banked (under standardized conditions) for later testing. We also recommend that sufficient blood be drawn to allow for planned testing of the primary hypothesis being addressed in the trial, and that additional baseline and posttreatment blood is banked for testing novel hypotheses (or generating new hypotheses) that arise in the field.

本文言語English
ページ(範囲)3064-3076
ページ数13
ジャーナルClinical Cancer Research
17
10
DOI
出版ステータスPublished - 2011 5月 15
外部発表はい

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究

フィンガープリント

「Recommendations from the iSBTc-SITC/FDA/NCI workshop on immunotherapy biomarkers」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル